C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome

April 21, 2026 updated by: Ryan T. Hurt, M.D., Ph.D., Mayo Clinic
The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

10

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Mayo Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients from the Post Covid Care Clinic (PCoCC) through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.

Description

Inclusion Criteria:

  • Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine & Health Section or approval by MAGPIES research group.
  • Be able to participate fully in all aspects of the study.
  • Have understood and signed study informed consent.

Exclusion Criteria:

  • Lacking the capacity to consent.
  • Prisoners and institutionalized individuals.

  • Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.

    o Acceptable forms include:

    • Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
    • Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
    • Intrauterine device (IUD)
    • Total hysterectomy or tubal ligation
    • Abstinence (no sex).
  • Those patients that have implants that would prevent them from having a PET Scan.
  • Patients that have claustrophobia.
  • Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Post Covid Syndrome
PET imaging through the C11 ER176 tracer
Drug: C11 ER176 Tracer
C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Degree of Neuroinflammation
Time Frame: Baseline reading only
Estimation of areas degree of neuroinflammation determined by the radiologist
Baseline reading only

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Mayo Clinic

Investigators

  • Principal Investigator: Ryan T. Hurt, MD, PhD, Mayo Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

April 7, 2026

First Submitted That Met QC Criteria

April 7, 2026

First Posted (Actual)

April 14, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 23-003731

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID-19

Clinical Trials on C11 ER176 Tracer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe